Saturday , November 18 2017
Home / Conditions / Prediabetes / Stanley Schwartz, MD, Q4: Why Sulfonylureas Should No Longer Be Used

Stanley Schwartz, MD, Q4: Why Sulfonylureas Should No Longer Be Used

Dr. Stanley Schwartz talks about why he doesn’t think that sulfonylureas should be used any longer, emphasizing that although they were useful when there were no alternatives, there are far safer and better drugs available today.

More videos in this series with Dr. Schwartz


{mainvote}

Stanely_Schwartz_MDStanley Schwartz, MD, has been awarded the honor of being a TOP DOC by Philadelphia Magazine many times over the years, including 2009, 2010 and 2011 for the treatment of diabetes and metabolic syndrome. For over 30 years, Dr. Schwartz was an Associate Professor at the University of Pennsylvania, most recently directing the Diabetes Program at the Philadelphia Heart Institute. Dr. Stanley Schwartz is a new Affiliate of the Main Line Health System, and an Emeritus Associate Professor of Medicine at the University of Pennsylvania, currently in a private practice in Ardmore, Pa. Dr. Schwartz received his MD in 1973 from the University of Chicago in Chicago, Illinois. He then completed his residency at the University of Pennsylvania, followed by a fellowship in endocrinology and metabolism at the University of Chicago.
Dr. Schwartz serves on the following Advisory Boards: Eli Lilly, Inc.; Amylin Pharmaceuticals; Takeda; Janssen; sanofi-aventis; and Santarus
He is also part of the following speaker’s bureaus: Merck; Eli Lilly;  Amylin Pharmaceuticals; Takeda; Santarus; BMS; Astra-Zeneca; and Novo Novartis.
Diabetes In Control is honored to also have Dr. Schwartz on our Advisory Board as well as a frequent contributor to our newsletters. You can find all of Dr. Schwartz’s Diabetes In Control articles here.